Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) has been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company.
Several brokerages recently weighed in on CZMWY. The Goldman Sachs Group cut shares of Carl Zeiss Meditec from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Sanford C. Bernstein cut shares of Carl Zeiss Meditec to a “market perform” rating in a report on Monday, January 26th.
Check Out Our Latest Stock Analysis on Carl Zeiss Meditec
Carl Zeiss Meditec Trading Up 1.8%
About Carl Zeiss Meditec
Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.
The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.
Read More
- Five stocks we like better than Carl Zeiss Meditec
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.
